Human IgG Neutralizing Monoclonal Antibodies Block SARS-CoV-2 Infection

Jinkai Wan,Shenghui Xing,Longfei Ding,Yongheng Wang,Chenjian Gu,Yanling Wu,Bowen Rong,Cheng Li,Siqing Wang,Kun Chen,Chenxi He,Dandan Zhu,Songhua Yuan,Chengli Qiu,Chen Zhao,Lei Nie,Zhangzhao Gao,Jingyu Jiao,Xiaoyan Zhang,Xiangxi Wang,Tianlei Ying,Haibin Wang,Youhua Xie,Yanan Lu,Jianqing Xu,Fei Lan

DOI: https://doi.org/10.1016/j.celrep.2020.107918

2020-01-01

SSRN Electronic Journal

Abstract:The coronavirus induced disease 19 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has become a worldwide threat to human lives, and neutralizing antibodies present a great therapeutic potential in curing affected patients. We purified more than one thousand memory B cells specific to SARS-CoV-2 S1 or RBD (receptor binding domain) antigens from 11 convalescent COVID-19 patients, and a total of 729 naturally paired heavy and light chain fragments were obtained by single B cell cloning technology. Among these, 178 recombinant monoclonal antibodies were tested positive for antigen binding, and the top 13 binders with K d below 0.5 nM are all RBD binders. Importantly, all these 13 antibodies could block pseudoviral entry into HEK293T cells overexpressing ACE2, with the best ones showing IC50s around 2-3 nM. We further identified 8 neutralizing antibodies against authentic virus with IC50s within 10 nM. Among these, 414-1 blocked authentic viral entry at IC50 of 1.75 nM and in combination with 105-38 could achieve IC50 as low as 0.45 nM. Meanwhile, we also found that 3 antibodies could cross-react with the SARS-CoV spike protein. Altogether, our study provided a panel of potent human neutralizing antibodies for COVID19 as therapeutics candidates for further development.